<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A3368663-738E-4607-A111-60039CE8C751"><gtr:id>A3368663-738E-4607-A111-60039CE8C751</gtr:id><gtr:name>European Science Foundation (ESF)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Research and Enterprise Services</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A3368663-738E-4607-A111-60039CE8C751"><gtr:id>A3368663-738E-4607-A111-60039CE8C751</gtr:id><gtr:name>European Science Foundation (ESF)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CF01032C-2181-463C-80E3-048F46496A04"><gtr:id>CF01032C-2181-463C-80E3-048F46496A04</gtr:id><gtr:firstName>Catharien</gtr:firstName><gtr:otherNames>Maria</gtr:otherNames><gtr:surname>Hilkens</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5081573E-57E1-478F-A3E1-D859940DA4CC"><gtr:id>5081573E-57E1-478F-A3E1-D859940DA4CC</gtr:id><gtr:firstName>Alexei</gtr:firstName><gtr:surname>von Delwig</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DA55209F-CA32-4BEF-A1E1-EB8A5EEC1E33"><gtr:id>DA55209F-CA32-4BEF-A1E1-EB8A5EEC1E33</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>Robinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/57A37958-62F0-4123-94F1-B401A3343848"><gtr:id>57A37958-62F0-4123-94F1-B401A3343848</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Dudley</gtr:otherNames><gtr:surname>Isaacs</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0601211"><gtr:id>2A6CC56C-B79B-4920-8AEA-F398535E3A80</gtr:id><gtr:title>Immunotherapy with dendritic cells in a humanised mouse model of rheumatoid arthritis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601211</gtr:grantReference><gtr:abstractText>We aim to develop a new therapy for rheumatoid arthritis (RA) using a type of immune cell called a dendritic cell (DC). RA is a painful disease that leads to stiffness and deformity of joints in hands, feet and limbs. Almost 400,000 people in the UK suffer from RA. No cure for this disease is available yet.

RA is caused by a patient?s own immune system: white blood cells mistakenly attack joints and cause destruction of cartilage and bone. We have made a special type of DC with the ability to prevent white blood cells attacking the joint (i.e. make the blood cells ?tolerant?) and hope this can be used to treat RA. This type of DC is called tolerogenic DC (tolDC).

Our work addresses important questions that must be answered before we can test tolDC treatment in humans. For instance, we need to know how many tolDC will be required to inhibit arthritis; where they will have to be injected (e.g. in the blood, in the joint); how long they will survive in the body; and how they make white blood cells tolerant. We will address these questions using mice which develop a disease similar to RA.

If successful, our work will bring a new and hopefully beneficial treatment for RA closer to clinical use.</gtr:abstractText><gtr:technicalSummary>Tolerogenic dendritic cells (tolDC) are immunoregulatory antigen presenting cells which suppress pro-inflammatory immune responses in mice and man in vivo. We have generated human and mouse tolDC with potent immunoregulatory activity by treating DC with the immunosuppressive drugs dexamethasone and vitamin D3. In a pilot study we have found that these tolDC inhibited collagen-induced arthritis in mice, and our ultimate goal is to develop tolDC vaccines as a therapeutic modality for rheumatoid arthritis (RA). Before this immunomodulatory treatment can be considered for use in the clinic, however, critical questions need to be addressed. We propose to study this experimental antigen-specific immunotherapy in a ?humanised? HLA-DR1 transgenic mouse model of arthritis. Our model is relevant to human RA, as HLA-DR1 is strongly associated with RA. In mice, it also confers susceptibility to arthritis induced by human type II collagen, a relevant candidate autoantigen of human RA. The aims of the current proposal are to determine and optimise the immunotherapeutic action of tolDC in arthritis, and to investigate the mechanism of tolerance induction in vivo. The specific objectives are to:
i) determine the effectiveness of tolDC treatment at different stages of arthritis, using both prophylactic and therapeutic regimes 
ii) optimise the therapeutic action of tolDC by defining optimal dose and route of administration (intravenous, sub-cutaneous, intra-articular)
iii) study the in vivo trafficking and survival of tolDC, utilising both magnetic resonance imaging and fluorescein tagging. We hypothesise that maximal immunoregulatory effects will require a proportion of the administered cells to reach local and/or regional lymph nodes.
iv) investigate the mechanism(s) underlying induction of antigen-specific tolerance. Based on existing information, we hypothesise that disease modulation will be associated with the emergence of regulatory T-cell populations.
Our work will increase our knowledge of these cells, and of immunomodulatory therapy in general. It will provide essential pre-clinical data, bringing this novel treatment closer to clinical application.</gtr:technicalSummary><gtr:fund><gtr:end>2010-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>385581</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>van Eden</gtr:description><gtr:id>1DE27083-C6E5-4756-9F95-39CED722DE8D</gtr:id><gtr:impact>The Dutch 'Reumafonds' awarded a grant to the van Eden group to investigate whether hsp-peptide loaded tolDC can induce therapeutic tolerance in a mouse model. Hilkens and Isaacs are named collaborators on the grant.

Van Eden and van Laar have been awarded a grant (co-funded by NWO and Reumafonds) to conduct a clinical trial with hsp-loaded tolDC in RA patients. They will make use of the tolDC developed in Newcastle by Hilkens and Isaacs, and bot Hilkens and Isaacs will act as collaborators.</gtr:impact><gtr:partnerContribution>The van Eden group have longstanding experience in the field of heat shock proteins. They have identified a HSP-derived peptide that promotes expansion of T regulatory cells. The collaborative idea is to load tolDC with this HSP-derived peptide to induce immune tolerance in RA patients.</gtr:partnerContribution><gtr:piContribution>We have developed a protocol to generate tolerogenic dendritic cells (tolDC) that have proven immunoregulatory action in vivo (mice) and in vitro (human). We have also conducted a first safety trial with tolDC in RA patients. We are now working with the van Eden group to 'load' our tolDC with relevant antigen.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Science Foundation (ESF)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>European Cooperation in Science and Technology (COST)</gtr:department><gtr:description>COST network</gtr:description><gtr:id>334D670A-B3B0-4B0A-A39C-57E8D15C836E</gtr:id><gtr:impact>This collaboration is multidisciplinary - we are working closely together with a computer scientist (Dr. Phil Lord, Newcastle University) to set up a minimum information model for tolerogenic antigen presenting cells (MITAP), in order to standardise the reporting of data in our field.

MITAP has now been published:
Lord P, Spiering R, Aguillon JC, Anderson AE, Appel S, Benitez-Ribas D, Ten
Brinke A, Broere F, Cools N, Cuturi MC, Diboll J, Geissler EK, Giannoukakis N,
Gregori S, van Ham SM, Lattimer S, Marshall L, Harry RA, Hutchinson JA, Isaacs
JD, Joosten I, van Kooten C, Lopez Diaz de Cerio A, Nikolic T, Oral HB,
Sofronic-Milosavljevic L, Ritter T, Riquelme P, Thomson AW, Trucco M, Vives-Pi M,
Martinez-Caceres EM, Hilkens CM. Minimum information about tolerogenic
antigen-presenting cells (MITAP): a first step towards reproducibility and
standardisation of cellular therapies. PeerJ. 2016 Aug 30;4:e2300. doi:
10.7717/peerj.2300. PubMed PMID: 27635311; PubMed Central PMCID: PMC5012269.</gtr:impact><gtr:partnerContribution>The COST network does dot provide funding for research, but does provide funding for networking e.g. workgroup meetings (travel costs, accommodation, subsistence), short visits to a collaborators' laboratory, workshops and training schools. The current spending is around 95000 Euro per year.</gtr:partnerContribution><gtr:piContribution>Together with colleagues in the Netherlands and Spain, Hilkens has set up a European COST (European Cooperation in Science and Technology) network on tolerogenic cellular therapies. The goal of this network is to accelerate the translation of novel cellular therapies for tolerance induction into the clinic. Hilkens is the leader of Workgroup1 which focusses on tolerogenic dendritic cells. She organises and chairs two WG1 meeting per year - these meetings are attended by 50 participants from 18 different European countries. The COST network has already resulted in several EU Horizon 2020 grant applications, and Hilkens was involved in 2 applications.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Beacon society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>03DEAA16-55F2-4918-8C55-D350B146022A</gtr:id><gtr:impact>One team member spoke spoke at Hexham Beacon Club (society for retired people) which meets at Trinity Methodist Church, Beaumont Street, Hexham, NE46 3LS on the 16th October 2013. The title of the talk was &amp;quot;Development of new therapies for Rheumatoid Arthritis&amp;quot;.

Several volunteers came forward after the talk to donate blood for a study we are conducting on the response to therapeutic antibodies in the young versus the elderly.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Arthritis Matters</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>041369E4-BD6E-4E70-9640-643B72F50302</gtr:id><gtr:impact>The Open Day 'Arthritis Matters' informed patients and carers on the latest developments in arthritis research. After the talks, there were a number of round table discussion in which patients, carers, medical doctors and scientist discussed various issues, including: living with chronic pain, loneliness, donating of samples for research. The team member presented the tolerogenic dendritic cell therapy work and took part in the latter round table discussion.

None yet. But feedback on the day was very good - participants enjoyed it.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.musculoskeletalresearch.com/2014/07/arthritis-matters-2014.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture Cafe Scientifique</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3C966696-42A4-4A0C-8EBB-DF815540AC09</gtr:id><gtr:impact>CH gave a lecture on: &amp;quot;Cellular therapies - from the laboratory to the clinic&amp;quot;. The lecture was based on our own experience with developing a tolerogenic dendritic cell-based therapy for rheumatoid arthritis. As a result, CH got invited to take part in another public engagement event, organised by the New Scientist Magazine.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://youtu.be/Y1ESfJBxvqY</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient group lecture - Newcastle</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BECC995D-CE25-4ADD-9E6E-64CEFD1C00D0</gtr:id><gtr:impact>Lecture to patients at the National Rheumatoid Arthritis Society meeting in Newcastle, April 2009.

The number of patients volunteering for clinical trials has increased.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Educational Day - London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>54DED01D-EE72-46E0-9731-1E2F62BC72C2</gtr:id><gtr:impact>Lecture to RA patients at the 'Early Rheumatoid Arthritis Network Educational Day' in London, November 2009.

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient group lecture - Cumbria</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B8C0C03F-E8F1-4C9A-B989-58DAD53C40AE</gtr:id><gtr:impact>Lecture to patients at the National Rheumatoid Arthritis Society meeting in Cumbria, October 2009.

The number of patients volunteering for clinical trials has increased.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Students for Students</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9B825138-6E54-494B-B1AE-058180FE84DA</gtr:id><gtr:impact>The meeting 'Immunology: translational perspectives' in York was entirely organised by Medical students, and the target audience were Medical students (not the typical academic audience).

None so far</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>49523</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR/BRC</gtr:department><gtr:description>NIHR Newcastle Biomedical Research Centre Project BH142386</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:fundingRef>BH142386</gtr:fundingRef><gtr:id>AD4FA658-C459-4E25-9B68-262EDE920D00</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>JGWP Project grant/JGWP Foundation</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>The JGW Patterson Foundation</gtr:fundingOrg><gtr:id>CDD21F60-BFD1-43DA-B9DD-1170613932D5</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>192000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Horizon 2020</gtr:department><gtr:description>Marie Sklodowska Curie</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>692FE17B-5101-44C3-9BE2-E90CEDA0F5DA</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>216411</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK Experimental Medicine Grant</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>18155</gtr:fundingRef><gtr:id>29CD74E1-0330-4283-8C4E-5A37A0B9E227</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cellular Therapies Facilities and Training</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>9737E924-1457-4D8D-BFD0-5192F5EC2F95</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We have developed a cellular therapy with tolerogenic dendritic cells (tolDC). Under the MRC award, we have generated important proof-of-principle data that tolDC can be effective as a therapeutic tool for inflammatory arthritis. TolDC were generated by treating mouse bone-marrow derived DC with a combination of immunosuppressive drugs and lipopolysaccharide. These tolDC significantly suppressed clinical symptoms of inflammatory arthritis in mice with established disease. 
We have recently completed a phase I safety trial with tolD in RA patients, funded by an ARUK Experimental Medicine Grant. Results of the trial show that the therapy is safe.</gtr:description><gtr:id>7C0E11BD-A67C-499E-BFCE-6051B5C8B4FA</gtr:id><gtr:impact>Our work on the therapeutic effects of murine tolDC in a mouse model of rheumatoid arthritis (RA) has been essential for developing tolDC therapy for RA patients. We have recently started a Phase I safety trial with tolDC in RA patients (funded by Arthritis Research UK) and the mouse tolDC data have been incorporated in all the formal, regulatory documents relating to the trial, as essential proof-of-principle, pre-clinical data. So far the data from the clinical trial indicate that tolDC treatment is safe.</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>tolDC</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=12108</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BC36D25B-6F5A-49F4-8850-902B0741F5A0"><gtr:id>BC36D25B-6F5A-49F4-8850-902B0741F5A0</gtr:id><gtr:title>Low-strength T-cell activation promotes Th17 responses.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d260818fbc78a4e02839bf794a1bec1f"><gtr:id>d260818fbc78a4e02839bf794a1bec1f</gtr:id><gtr:otherNames>Purvis HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/036B1A17-F05B-43EA-83A9-D19E7F5888CE"><gtr:id>036B1A17-F05B-43EA-83A9-D19E7F5888CE</gtr:id><gtr:title>Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9622f442a4ef84161e8a09e76d5a5d16"><gtr:id>9622f442a4ef84161e8a09e76d5a5d16</gtr:id><gtr:otherNames>Stoop JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D2D49F91-9F35-433D-B8A2-D583B7959B58"><gtr:id>D2D49F91-9F35-433D-B8A2-D583B7959B58</gtr:id><gtr:title>Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models?</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9622f442a4ef84161e8a09e76d5a5d16"><gtr:id>9622f442a4ef84161e8a09e76d5a5d16</gtr:id><gtr:otherNames>Stoop JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601211</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>